Key result
Combined KU-55933 and apicidin cuts disturbed flow-induced endothelial proliferation by ~73% and reduces atherosclerosis in mice.
Answers are grounded in this paper and cite their sources.
Several compounds have been used for atherosclerosis treatment, including clinical trials; however, no anti-atherosclerotic drugs based on hemodynamic force-mediated atherogenesis have been discovered. Our previous studies demonstrated that “small mothers against decapentaplegic homolog 1/5” (Smad1/5) is a convergent signaling molecule for chemical [e.g., bone morphogenetic proteins (BMPs)] and mechanical (e.g., disturbed flow) stimulations and hence may serve as a promising hemodynamic-based target for anti-atherosclerosis drug development. The goal of this study was to develop a high-throughput screening (HTS) platform to identify potential compounds that can inhibit disturbed flow- and BMP-induced Smad1/5 activation and atherosclerosis. Through HTS using a Smad1/5 downstream target inhibitor of DNA binding 1 ( Id-1 ) as a luciferase reporter, we demonstrated that KU-55933 and Apicidin suppressed Id-1 expression in AD-293 cells. KU-55933 (10 μM), Apicidin (10 μM), and the combination of half doses of each [1/2(K + A)] inhibited disturbed flow- and BMP4-induced Smad1/5 activation in human vascular endothelial cells (ECs). KU-55933, Apicidin, and 1/2(K + A) treatments caused 50.6%, 47.4%, and 73.3% inhibitions of EC proliferation induced by disturbed flow, respectively, whereas EC inflammation was only suppressed by KU-55933 and 1/2(K + A), but not Apicidin alone. Administrations of KU-55933 and 1/2(K + A) to apolipoprotein E-deficient mice inhibited Smad1/5 activation in ECs in athero-susceptible regions, thereby suppressing endothelial proliferation and inflammation, with the attenuation of atherosclerotic lesions in these mice. A unique drug screening platform has been developed to demonstrate that KU-55933 and its combination with Apicidin are promising therapeutic compounds for atherosclerosis based on hemodynamic considerations.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2024) studied Atherosclerosis. KU-55933, Apicidin, and half-dose combination [1/2(K + A)] was evaluated on Inhibition of disturbed flow-induced endothelial cell proliferation and attenuation of atherosclerotic lesions. KU-55933, Apicidin, and their half-dose combination inhibited disturbed flow-induced endothelial cell proliferation by 50.6%, 47.4%, and 73.3%, respectively, and attenuated lesions in ApoE-/- mice.
Synapse has enriched 10 related papers. Consider them for comparative context: